LENZ Therapeutics Inc (NASDAQ: LENZ)’s stock price has soared by 11.03% in relation to previous closing price of $31.36. Nevertheless, the company has seen a gain of 15.87% in its stock price over the last five trading days. globenewswire.com reported 2025-07-07 that SAN DIEGO and CLERMONT-FERRAND, France, July 07, 2025 (GLOBE NEWSWIRE) — LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Laboratoires Théa (“Théa”) announced an exclusive license and commercialization agreement for Théa to register and commercialize LNZ100 for the treatment of presbyopia in Canada. LENZ Therapeutics is a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, which has a US FDA PDUFA date of August 8, 2025.
Is It Worth Investing in LENZ Therapeutics Inc (NASDAQ: LENZ) Right Now?
Additionally, the 36-month beta value for LENZ is 0.50. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for LENZ is 22.47M and currently, short sellers hold a 15.13% ratio of that float. The average trading volume of LENZ on July 10, 2025 was 268.96K shares.
LENZ’s Market Performance
LENZ’s stock has seen a 15.87% increase for the week, with a 8.95% rise in the past month and a 78.56% gain in the past quarter. The volatility ratio for the week is 6.86%, and the volatility levels for the past 30 days are at 7.26% for LENZ Therapeutics Inc The simple moving average for the past 20 days is 15.11% for LENZ’s stock, with a 26.95% simple moving average for the past 200 days.
Analysts’ Opinion of LENZ
Many brokerage firms have already submitted their reports for LENZ stocks, with Piper Sandler repeating the rating for LENZ by listing it as a “Overweight.” The predicted price for LENZ in the upcoming period, according to Piper Sandler is $51 based on the research report published on April 14, 2025 of the current year 2025.
TD Cowen, on the other hand, stated in their research note that they expect to see LENZ reach a price target of $60. The rating they have provided for LENZ stocks is “Buy” according to the report published on March 18th, 2025.
Raymond James gave a rating of “Outperform” to LENZ, setting the target price at $37 in the report published on September 27th of the previous year.
LENZ Trading at 19.36% from the 50-Day Moving Average
After a stumble in the market that brought LENZ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -10.56% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LENZ starting from Versant Venture Capital VI, L., who sale 200,000 shares at the price of $30.46 back on Jun 27 ’25. After this action, Versant Venture Capital VI, L. now owns 1,767,275 shares of LENZ Therapeutics Inc, valued at $6,093,000 using the latest closing price.
Versant Venture Capital VI, L., the 10% Owner of LENZ Therapeutics Inc, sale 133,924 shares at $30.25 during a trade that took place back on Jun 20 ’25, which means that Versant Venture Capital VI, L. is holding 1,967,275 shares at $4,051,201 based on the most recent closing price.
Stock Fundamentals for LENZ
The total capital return value is set at -0.31. Equity return is now at value -24.47, with -22.81 for asset returns.
Based on LENZ Therapeutics Inc (LENZ), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -43.57.
Currently, EBITDA for the company is -49.71 million with net debt to EBITDA at 0.37. The liquidity ratio also appears to be rather interesting for investors as it stands at 23.09.
Conclusion
In conclusion, LENZ Therapeutics Inc (LENZ) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
